Literature DB >> 23073283

Comparative assessment of published atrial fibrillation stroke risk stratification schemes for predicting stroke, in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study.

Gregory Y H Lip1, Hung-Ju Lin, Kuo-Liong Chien, Hsiu-Ching Hsu, Ta-Chen Su, Ming-Fong Chen, Yuan-Teh Lee.   

Abstract

BACKGROUND: In patients at high risk of stroke, such as atrial fibrillation (AF), there has been great interest in developing stroke risk prediction schemes for identifying those at high risk of stroke. Stroke risk prediction schemes have also been developed in non-AF populations, but are limited by lack of simplicity, which is more evident in schemes used in AF populations. We hypothesized that contemporary stroke risk stratification schemes used in assessing AF patients could predict stroke and thromboembolism in a non-AF community population, comparably to that seen in AF populations.
METHODS: We tested the CHADS2 and CHA2DS2-VASc schemes, as well as the AF stroke risk stratification schemes from the Framingham study, Rietbrock et al., 2006 ACC/AHA/ESC guidelines, the 8th American College of Cardiology (ACCP) guidelines and NICE, for predicting stroke in a large community cohort of non-AF subjects, the Chin-Shan Community Cohort Study.
RESULTS: The tested schemes had variable classification into low, moderate and high risk strata, with the proportion classified as low risk ranging from 5.4% (Rietbrock et al. to 59.0% (CHADS2 classical). Rates of stroke also varied in those classified as 'low risk' ranging from 1.1% (Rietbrock et al. to 3.5% (Framingham). All common risk schemes had broadly similar c-statistics, ranging from 0.658 (Framingham) to 0.728 (CHADS2 classical) when assessed as a continuous risk variable for predicting stroke in this population, with clear overlap between the 95% CIs. In an exploratory analysis amongst AF subjects in our population, the c-statistics were broadly similar to those seen in non-AF subjects.
CONCLUSION: Contemporary stroke risk stratification schema used for AF can also be applied to non-AF populations with a similar (modest) predictive value. Given their simplicity (e.g. CHADS2 score), these scores could potentially be used for a 'quick' evaluation of stroke risk in non-AF populations, in a similar manner to AF populations.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; CHADS(2); Stroke risk stratification

Mesh:

Year:  2012        PMID: 23073283     DOI: 10.1016/j.ijcard.2012.09.148

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  19 in total

1.  Pulmonary Embolism in Acute Asthma Exacerbation: Clinical Characteristics, Prediction Model and Hospital Outcomes.

Authors:  Bashar N Alzghoul; Raju Reddy; Mwelwa Chizinga; Ayoub Innabi; Baiming Zou; Eric S Papierniak; Ibrahim Faruqi
Journal:  Lung       Date:  2020-05-18       Impact factor: 2.584

2.  Low homoarginine/SDMA ratio is associated with poor short- and long-term outcome after stroke in two prospective studies.

Authors:  Chi-Un Choe; Susanne Lezius; Kathrin Cordts; Christian Gerloff; Rainer H Böger; Edzard Schwedhelm; Peter J Grant
Journal:  Neurol Sci       Date:  2019-09-03       Impact factor: 3.307

3.  Carotid artery molecular calcification assessed by [18F]fluoride PET/CT: correlation with cardiovascular and thromboembolic risk factors.

Authors:  Simon A Castro; Daniele Muser; Hwan Lee; Emily C Hancin; Austin J Borja; Oswaldo Acosta; Thomas J Werner; Anders Thomassen; Caius Constantinescu; Poul Flemming Høilund-Carlsen; Abass Alavi
Journal:  Eur Radiol       Date:  2021-04-17       Impact factor: 5.315

4.  CHA2DS2-VASC Score Predicts the Risk of Stroke in Patients Hospitalized to the Internal Medicine Department Without Known Atrial Fibrillation.

Authors:  Karney Lahad; Elad Maor; Robert Klempfner; Chagai Grossman; Amit Druyan; Ilan Ben-Zvi
Journal:  J Gen Intern Med       Date:  2022-05-27       Impact factor: 6.473

5.  Relation of the CHA2DS2-VASc Score to Risk of Thrombotic and Embolic Stroke in Community-Dwelling Individuals Without Atrial Fibrillation (From The Atherosclerosis Risk in Communities [ARIC] Study).

Authors:  Ryan J Koene; M Chadi Alraies; Faye L Norby; Elsayed Z Soliman; Ankit Maheshwari; Gregory Y H Lip; Alvaro Alonso; Lin Y Chen
Journal:  Am J Cardiol       Date:  2018-11-06       Impact factor: 2.778

6.  The association of CHA2DS2-VASc score and blood biomarkers with ischemic stroke outcomes: the Belgrade stroke study.

Authors:  Tatjana S Potpara; Marija M Polovina; Dijana Djikic; Jelena M Marinkovic; Nikola Kocev; Gregory Y H Lip
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

7.  The CHA2DS2-VASc score as a predictor of high mortality in hospitalized heart failure patients.

Authors:  Akiomi Yoshihisa; Shunsuke Watanabe; Yuki Kanno; Mai Takiguchi; Akihiko Sato; Tetsuro Yokokawa; Shunsuke Miura; Takeshi Shimizu; Satoshi Abe; Takamasa Sato; Satoshi Suzuki; Masayoshi Oikawa; Nobuo Sakamoto; Takayoshi Yamaki; Koichi Sugimoto; Hiroyuki Kunii; Kazuhiko Nakazato; Hitoshi Suzuki; Shu-Ichi Saitoh; Yasuchika Takeishi
Journal:  ESC Heart Fail       Date:  2016-07-18

8.  CHA2DS2-VASC score predicts coronary artery disease progression and mortality after ventricular arrhythmia in patients with implantable cardioverter-defibrillator.

Authors:  Refik Kavsur; Marc Ulrich Becher; Welat Nassan; Alexander Sedaghat; Adem Aksoy; Jan Wilko Schrickel; Georg Nickenig; Vedat Tiyerili
Journal:  Int J Cardiol Heart Vasc       Date:  2021-05-25

9.  Determinants and Time Trends for Ischaemic and Haemorrhagic Stroke in a Large Chinese Population.

Authors:  Yutao Guo; Hao Wang; Tao Tao; Yingchun Tian; Yutang Wang; Yundai Chen; Gregory Y H Lip
Journal:  PLoS One       Date:  2016-09-29       Impact factor: 3.240

10.  Junctional bradycardia is a potential risk factor of stroke.

Authors:  Gwang Sil Kim; Jae-Sun Uhm; Tae-Hoon Kim; Hancheol Lee; Junbeom Park; Jin-Kyu Park; Boyoung Joung; Hui-Nam Pak; Moon-Hyoung Lee
Journal:  BMC Neurol       Date:  2016-07-25       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.